Cleared Special

CONTOUR® NEXT GEN Blood Glucose Monitoring System (K223293) - FDA 510(k) Clearance

Class II Chemistry device cleared through the Special 510(k) pathway - typically does not require clinical trials.

K223293 · Ascensia Diabetes Care U.S., Inc. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2022
Decision
23d
Days
Class 2
Risk

K223293 is an FDA 510(k) clearance for the CONTOUR® NEXT GEN Blood Glucose Monitoring System. Classified as System, Test, Blood Glucose, Over The Counter (product code NBW), Class II - Special Controls.

Submitted by Ascensia Diabetes Care U.S., Inc. (Valhalla, US). The FDA issued a Cleared decision on November 18, 2022 after a review of 23 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Ascensia Diabetes Care U.S., Inc. devices

Submission Details

510(k) Number K223293 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 26, 2022
Decision Date November 18, 2022
Days to Decision 23 days
Submission Type Special
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
65d faster than avg
Panel avg: 88d · This submission: 23d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code NBW System, Test, Blood Glucose, Over The Counter
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1345
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - NBW System, Test, Blood Glucose, Over The Counter

All 165
Devices cleared under the same product code (NBW) and FDA review panel - the closest regulatory comparables to K223293.
ReliOn Premier BLU Blood Glucose Monitoring System
K230625 · I-Sens, Inc. · Aug 2023
MIO Blood Glucose Monitoring System
K223722 · Mio Labs, Inc. · Jun 2023
GlucoSure ADVANCE Link Blood Glucose Monitoring System
K222234 · Apex BioTechnology Corp. · Dec 2022
BGM039 Blood Glucose Monitoring System, BGM039 Link Blood Glucose Monitoring System
K220421 · Apex BioTechnology Corp. · Nov 2022
SuperCheck Pro Blood Glucose Monitoring System
K213061 · Ok Biotech Co., Ltd. · Oct 2022
GlucoLeader Enhance 2 Blood Glucose Monitoring System
K212248 · Hmd Biomedical, Inc. · Aug 2022